Beremagene geperpavec-svdt (B-VEC) entered the market in 2023 as the first approved corrective treatment for dystrophic epidermolysis bullosa (DEB), a rare genetic disease affecting the skin and nails ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback